In the United States, over 35 million women live with an autoimmune disease1, yet less than 1% of women’s health funding is allocated to these conditions2. The impact is extensive: women often spend years trying to get a diagnosis, face daily symptoms that disrupt work and family life, and have
The Disproportionate Burden of Autoimmune Disease in Women Autoimmune disease is a women’s health issue! Autoimmune and autoinflammatory diseases (AIIDs) afflict more than 35 million women in the United States alone1. According to the National Institutes of Health (NIH), 75-80% of autoimmune patients are female. These disparities are most evident
Why is a patient-first strategy mission-critical for digital health companies? My passion for strategic patient-first care is built on decades of living with autoimmune disease and advocacy for the invisible autoimmune epidemic. Despite affecting as many people, autoimmune is 50 years behind cancer: under-recognized, under-researched, and with mostly underserved patients.
The Problem: We Don’t Really Know! The problem with estimating the total cost burden of the autoimmune disease (AIID) epidemic is that we really don’t know! A May 2022 NIH report validates our long-held belief that missing and inconsistent data for autoimmune diseases (AIIDs) are at the root of the
We have noticed much confusion among our broad digital health/virtual-first care network about the definitions of conventional, lifestyle, functional and alternative medicine. To add to the confusion, each picks and chooses techniques from the others to incorporate into their approach. For more than a decade, our team has focused on
NIH Report Shows Why The AIID Epidemic is Invisible An NIH research report on autoimmune disease, published May, 2022, explains why, despite affecting more Americans than cancer, autoimmune and immunoinflammatory diseases (AIIDs) remain an invisible epidemic. Autoimmunity is an orphaned research field of patchwork studies of some 80-150 individual diseases.
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
We’ve compiled some incidence, prevalence and growth estimates for selected autoimmune diseases (AIIDs) as a follow up to our previous post. In that post, we surveyed the sorry state of US national autoimmune incidence & prevalence data. Summary: Per the May 2022 NIH Report: Enhancing Autoimmune Research the US has
Since 2010, we have sought autoimmune disease (AIID) incidence and prevalence data. Despite efforts by independent organizations like AARDA/AA, AIR and many single disease groups, we never found total national autoimmune statistics. NIH/CDC statistics bury AIIDs within siloed categories: Arthritis, diabetes, or by medical specialty: rheumatology, neurology, dermatology, endocrine, etc.
We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an